[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GT200600350A - Formulaciones líquidas - Google Patents

Formulaciones líquidas

Info

Publication number
GT200600350A
GT200600350A GT200600350A GT200600350A GT200600350A GT 200600350 A GT200600350 A GT 200600350A GT 200600350 A GT200600350 A GT 200600350A GT 200600350 A GT200600350 A GT 200600350A GT 200600350 A GT200600350 A GT 200600350A
Authority
GT
Guatemala
Prior art keywords
liquid formulations
propilenic
swallow
dilution
concentrate
Prior art date
Application number
GT200600350A
Other languages
English (en)
Inventor
Vivian Christine Georgousis
Wei-Qin Tong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37734410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600350A publication Critical patent/GT200600350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE UN CONCENTRADO PARA DILUCION, QUE COMPRENDE UN AGONISTA DEL RECEPTOR S1P O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, GLICOL PROPILENICO Y OPCIONALMENTE GLICERINA. ESTA FORMULACION ESTA ADAPTADA PARA PACIENTES QUE TIENEN UNA CONDICION DE DIFICULTAD PARA TRAGAR.
GT200600350A 2005-08-09 2006-08-04 Formulaciones líquidas GT200600350A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70682005P 2005-08-09 2005-08-09

Publications (1)

Publication Number Publication Date
GT200600350A true GT200600350A (es) 2007-03-28

Family

ID=37734410

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600350A GT200600350A (es) 2005-08-09 2006-08-04 Formulaciones líquidas

Country Status (24)

Country Link
US (4) US20080194526A1 (es)
EP (1) EP1915130B1 (es)
JP (1) JP5068755B2 (es)
KR (1) KR101473494B1 (es)
CN (1) CN101237852B (es)
AR (1) AR056020A1 (es)
AU (1) AU2006280138B2 (es)
BR (1) BRPI0615009A2 (es)
CA (1) CA2618018C (es)
EC (1) ECSP088165A (es)
GT (1) GT200600350A (es)
HK (1) HK1123188A1 (es)
IL (1) IL188915A0 (es)
MA (1) MA29736B1 (es)
MX (1) MX2008001967A (es)
MY (1) MY145111A (es)
NO (1) NO20081218L (es)
NZ (2) NZ593121A (es)
PE (2) PE20070337A1 (es)
RU (2) RU2470631C2 (es)
TN (1) TNSN08061A1 (es)
TW (1) TWI317289B (es)
WO (1) WO2007021666A2 (es)
ZA (1) ZA200800640B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2359821A1 (en) * 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
EP2207791B2 (en) 2007-10-04 2019-08-07 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
DK2952177T3 (da) * 2007-10-12 2021-04-26 Novartis Ag Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
US20110236428A1 (en) 2008-10-21 2011-09-29 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
MX2011004924A (es) 2008-11-11 2011-05-30 Novartis Ag Sales de fingolimod.
CN104803902A (zh) * 2008-12-18 2015-07-29 诺华股份有限公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的半富马酸盐
BRPI0922457A2 (pt) * 2008-12-18 2015-12-15 Novartis Ag forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
RU2011129229A (ru) 2008-12-18 2013-01-27 Новартис Аг Новые соли
AU2010217605B2 (en) * 2009-02-24 2012-07-26 Novartis Ag Ceramide-analogous metabolites
US20100243087A1 (en) * 2009-03-03 2010-09-30 Millipore Corporation System and pump apparatus for processing fluid samples
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
WO2011109355A1 (en) 2010-03-01 2011-09-09 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
EA026144B9 (ru) 2011-01-07 2021-10-26 Новартис Аг Твердофазная фармацевтическая композиция, содержащая гемифумаратную соль 1-{4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил}азетидин-3-карбоновой кислоты, и таблетка, ее содержащая
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP6316422B2 (ja) 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
CA3074043A1 (en) 2017-09-27 2019-04-04 Novartis Ag Parenteral formulation comprising siponimod
US20200306222A1 (en) 2017-09-29 2020-10-01 Novartis Ag Dosing Regimen of Siponimod
EP3687530A1 (en) 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
WO2021214717A1 (en) 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) * 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
DE19645549A1 (de) * 1996-11-05 1998-05-07 Bayer Ag Verfahren zur Herstellung von 2-Methyl-2,4-diaminopentan
EP1002792B1 (en) * 1997-04-04 2004-07-14 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
US6727283B2 (en) * 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
JPWO2003020313A1 (ja) * 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
PT1431284E (pt) * 2001-09-27 2008-01-21 Kyorin Seiyaku Kk Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
ATE412408T1 (de) * 2002-05-16 2008-11-15 Novartis Pharma Gmbh Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
CA2539438A1 (en) * 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists

Also Published As

Publication number Publication date
AU2006280138B2 (en) 2010-03-04
KR101473494B1 (ko) 2014-12-16
HK1123188A1 (en) 2009-06-12
RU2470631C2 (ru) 2012-12-27
KR20080035608A (ko) 2008-04-23
JP2009504653A (ja) 2009-02-05
US20120328664A1 (en) 2012-12-27
AU2006280138A1 (en) 2007-02-22
TWI317289B (en) 2009-11-21
PE20070337A1 (es) 2007-04-18
CN101237852A (zh) 2008-08-06
NO20081218L (no) 2008-04-29
PE20100149A1 (es) 2010-03-24
TNSN08061A1 (en) 2009-07-14
BRPI0615009A2 (pt) 2011-05-03
JP5068755B2 (ja) 2012-11-07
TW200738277A (en) 2007-10-16
RU2008108887A (ru) 2009-09-20
CA2618018A1 (en) 2007-02-22
ECSP088165A (es) 2008-03-26
IL188915A0 (en) 2008-04-13
MA29736B1 (fr) 2008-09-01
US20160030572A1 (en) 2016-02-04
US20150080347A9 (en) 2015-03-19
WO2007021666A3 (en) 2007-05-31
EP1915130B1 (en) 2016-07-13
WO2007021666A2 (en) 2007-02-22
ZA200800640B (en) 2008-12-31
NZ593121A (en) 2012-09-28
RU2428180C2 (ru) 2011-09-10
CN101237852B (zh) 2011-01-26
US20080194526A1 (en) 2008-08-14
EP1915130A2 (en) 2008-04-30
MY145111A (en) 2011-12-30
NZ565696A (en) 2011-06-30
CA2618018C (en) 2016-05-31
RU2011106364A (ru) 2012-08-27
US20140179636A1 (en) 2014-06-26
MX2008001967A (es) 2008-03-26
AR056020A1 (es) 2007-09-12

Similar Documents

Publication Publication Date Title
GT200600350A (es) Formulaciones líquidas
CY1125100T1 (el) Υδατικο φαρμακευτικο σκευασμα ταπενταδολης για απο του στοματος χορηγηση
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
BR112012029653A2 (pt) formulação tópica para um inibidor jak
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CR20110110A (es) Composicion farmaceutica
BR112014019262A8 (pt) Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas
UY30460A1 (es) Compuestos terapéuticos
BR112012022873A2 (pt) formulações orais e sais lipofílicos de metilnaltrexona
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
SV2009003335A (es) Formulaciones para el cancer
PA8803201A1 (es) Derivados acidos de cicloalquilamino
BR112013004016A2 (pt) formulações á base de nalbufina e as respectivas utilizações
BR112014000290A2 (pt) formulações de combinação de darunavir
MX2010005013A (es) Composiciones intranasales.
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
GT200500378A (es) Macrolidos
BR112014000195A2 (pt) formulações de darunavir
CR20190144A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos
BR112012030654A2 (pt) formas de dosagem oral de bendamustina
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
GT201000107A (es) Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado.
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos